Searchable abstracts of presentations at key conferences in endocrinology

ea0032p21 | Adrenal cortex | ECE2013

Bilateral inferior petrosal sinus sampling in cushing's syndrome: comparison between an old and a new technique in naples experience

De Leo Monica , Tortora Fabio , Cozzolino Alessia , Simeoli Chiara , Iacuaniello Davide , Albano Aurora , Briganti Francesco , Cirillo Sossio , Colao Annamaria , Pivonello Rosario

Introduction: Bilateral inferior petrosal sinus sampling (BIPSS) is the test that offers the highest diagnostic accuracy in the differential diagnosis between pituitary and ectopic Cushng’s syndrome (CS). The aim of this study was to compare the diagnostic accuracy of BIPSS performed in the last six years, after the change in the technical procedure with that performed in the past period in Naples centre.Patients and methods: Seventeen patients with...

ea0032p115 | Calcium and Vitamin D metabolism | ECE2013

Cinacalcet in patients with primary hyperparathyroidism (PHPT): comparison between sporadic and MEN1 PHPT

Prete Michela Del , Marotta Vincenzo , Ramundo Valeria , Marciello Francesca , Carratu Anna Chiara , di Roseto Chiara De Luca , Esposito Raffaella , Di Sarno Antonella , Colao Annamaria , Faggiano Antongiulio

Introduction: PHPT is a common endocrine disease characterized by hypercalcemia and different degree of osteoporosis and nephrolithiasis. PHPT arises in the context of an inherited disease in 5% of cases. Multiple endocrine neoplasia type 1 (MEN1) is the commonest cause of inherited PHPT. The main therapeutic approach for PHPT is surgery, however many patients refuse or have contraindications for surgery while others, in particular those with MEN1 PHPT, have persistent/relapsi...

ea0032p520 | Endocrine tumours and neoplasia | ECE2013

Assessment of fatal events in patients with radio-active iodine (RAI)-refractory differentiated thyroid cancer responsive to treatment with sorafenib

Marotta Vincenzo , Del Prete Michela , Ramundo Valeria , Marciello Francesca , Di Sarno Antonella , Esposito Raffaella , Carratu Annachiara , de Luca di Roseto Chiara , Camera Luigi , Colao Annamaria , Faggiano Antongiulio

Introduction: Targeted therapy with the multi-kinase inhibitor sorafenib is effective for treatment of differentiated thyroid cancer (DTC) unresponsive to RAI. Although kinase-inhibitors (KIs) are usually well tolerated, severe and even fatal adverse events are reported. Aim of the study was to assess incidence and characteristics of fatal events in patients with RAI-refractory DTC responsive to treatment with sorafenib.Design: A retrospective analysis o...

ea0032p529 | Endocrine tumours and neoplasia | ECE2013

Familial malignant paraganglioma is long-term stabilized with the tyrosine-kinase inhibitor sunitinib

Ramundo Valeria , Marciello Francesca , Del Prete Michela , Marotta Vincenzo , Esposito Raffaella , Chiara Carratu Anna , de Luca di Roseto Chiara , Colao Annamaria , Faggiano Antongiulio

Introduction: Paragangliomas are neuroectodermal tumors that arise from adrenal medulla or extra-adrenal ganglia and are characterized by high vascularisation. A high rate of these tumours is genetically inherited. For malignant paragangliomas, chemo- and radio-therapy are potentially effective, but tumor response is of short duration and patient prognosis is quite poor. Sunitinib is a tyrosine-kinase inhibitor, targeting VEGFR1, -2, PDGFRα, -β, RET and c-Kit. Recent...

ea0032p541 | Endocrine tumours and neoplasia | ECE2013

Sequential use of the kinase-inhibitors sorafenib and sunitinib in a patient affected with pluri-metastatic iodine-refractory follicular thyroid carcinoma

Marotta Vincenzo , Ramundo Valeria , Marciello Francesca , Del Prete Michela , Di Sarno Antonella , Esposito Raffaella , Carratu Annachiara , de Luca di Roseto Chiara , Camera Luigi , Colao Annamaria , Faggiano Antongiulio

Introduction: Kinase-inhibitors (KIs) are effective for treatment of most aggressive endocrine cancers. The crucial point about treatment with KIs is that these agents are not curative and their effects are at best transitory and are always followed by a restoration of tumour growth and progression. Several retrospective and phase II studies demonstrated efficacy of both sorafenib and sunitib for treatment of iodine refractory differentiated thyroid cancer although results fro...

ea0032p654 | Male reproduction | ECE2013

Identification of vitamin D (VDR) and retinoic X (RXR) receptor in normal and neoplastic human reproductive tissues

Cariati Federica , Gigantino Vincenzo , Coppola Giorgio , Pivonello Claudia , Galdiero Mariano , Botti Gerardo , Gandini Loredana , Lenzi Andrea , Franco Renato , Colao Annamaria , Pivonello Rosario

Background: Vitamin D is an important modulator of cell growth, differentiation and death in normal and neoplastic cells. Its actions are mediated by vitamin D receptor (VDR), which heterodimerizes with nuclear retinoid X receptors (RXRα). Recently, it has been suggested that vitamin D system have a role in male reproduction. The aim of this study was to investigate the VDR and RXRα localization in normal and neoplastic human male reproductive tissues.<p class="a...

ea0032p830 | Pituitary–Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Mutations of SOX2 gene: a novel heterozygous mutation and impact on congenital hypopituitarism

Auriemma Renata S , Macchiaroli Annamaria , Kelberman Daniel , Faienza Maria F , Corona Rosalia , Mariano Iolanda , Giangiobbe Sara , Galdiero Mariano , Pivonello Rosario , Colao Annamaria , Gasperi Maurizio

Introduction: Anophthalmia/microphthalmia is a rare developmental craniofacial defect often associated to congenital hypopituitarism with GH deficiency and hypogonadism. SOX2 gene plays a key role in embryonic development regulation and heterozygous mutations of this gene, reported only in 14 patients to date, have been associated to anophthalmia/microphthalmia and congenital hypopituitarism in uo to 10% of cases. Therefore, the study of the SOX2 gene can be clinically useful ...

ea0032p845 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of a randomized, double-blind, multicenter, phase III study

Sheppard Michael , Bronstein Marcello , Freda Pamela , Serri Omar , De Marinis Laura , Naves Luciana , Rozhinskaya Liudmila , Hermosillo Resendiz Karina , Ruffin Matthieu , Asubonteng Kobby , Colao Annamaria

Introduction: Pasireotide LAR was significantly superior to octreotide LAR at providing biochemical control in a 12-month trial in 358 medically naïve patients with acromegaly. Patients with clinical benefit or GH <2.5 μg/l and IGF1≤ULN could continue therapy in the extension study.Methods: Patients entering the extension (pasireotide LAR, n=74; octreotide LAR, n=46) were followed up to month 26 (core plus extension)...

ea0032p866 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Effects of short (12 months) and long (60 months) term treatment with cabergoline on metabolic syndrome and visceral adiposity index in patients with hyperprolactinemia

Auriemma Renata S , Granieri Luciana , Perone Ylenia , Galdiero Mariano , Grasso Ludovica , Simeoli Chiara , Pivonello Claudia , Gasperi Maurizio , Giordano Carla , Colao Annamaria , Pivonello Rosario

Introduction: Hyperprolactinemia is reportedly associated with an impaired metabolic profile, particularly in patients with concomitant hypogonadism. The current study aimed at investigating the effects of short (12 months) and long (60 months) treatment with cabergoline (CAB) on metabolic complications, metabolic syndrome (MS) prevalence and visceral adiposity index (VAI) in hyperprolactinemic patients.Patients and methods: Seventy-one patients (51 F, 2...

ea0032p891 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Role of reversal of hypogonadism on the improvement of metabolic syndrome in male patients with hyperprolactinemia during chronic treatment with cabergoline

Galdiero Mariano , Auriemma Renata S , Calzo Fabio Lo , Vitale Pasquale , Pivonello Claudia , Cariati Federica , Perone Ylenia , Salzano Ciro , Colao Annamaria , Pivonello Rosario

Introduction: Generously supported by IPSEN)-->Hyperprolactinemia (HPRL) is associated with an impaired metabolic profile, particularly in patients with hypogonadism. This study aimed to: i) investigate the effects of short and long treatment with cabergoline (CAB) on the prevalence of metabolic syndrome (MS) and insulin sensitivity and ii) to evaluate the impact of gonadal function on metabolic changes, in male patients with HPRL.</...